| Target Price | €3.57 |
| Price | €1.83 |
| Potential |
95.08%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Lassila & Tikanoja 2027 .
The average Lassila & Tikanoja target price is €3.57.
This is
95.08%
register free of charge
€11.55
531.15%
register free of charge
€2.63
43.50%
register free of charge
|
|
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Lassila & Tikanoja stock has an average upside potential 2027 of
95.08%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million € | 770.70 | 787.44 |
| 3.91% | 2.17% | |
| EBITDA Margin | 11.38% | 13.87% |
| 3.11% | 21.89% | |
| Net Margin | -0.22% | 4.47% |
| 106.06% | 2,126.49% |
6 Analysts have issued a sales forecast Lassila & Tikanoja 2025 . The average Lassila & Tikanoja sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Lassila & Tikanoja EBITDA forecast 2025. The average Lassila & Tikanoja EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Lassila & Tikanoja Analysts have issued a net profit forecast 2025. The average Lassila & Tikanoja net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | -0.04 | 0.92 |
| 105.26% | 2,400.00% | |
| P/E | 2.74 |
6 Analysts have issued a Lassila & Tikanoja forecast for earnings per share. The average Lassila & Tikanoja EPS is
This results in the following potential growth metrics and future valuations:
Lassila & Tikanoja...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


